{
    "clinical_study": {
        "@rank": "38679", 
        "brief_summary": {
            "textblock": "This is a Phase II Trial of Perioperative Chemotherapy with Oxaliplatin, 5-Fluorouracil,\n      Leucovorin(MODIFIED FOLFOX6)in Patients with Locally Advanced Operable Gastric Cancer."
        }, 
        "brief_title": "Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "condition": "Advanced Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The main purpose of this study is to evaluate response rate (clinical response and\n      pathological response) of oxaliplatin, 5-fluorouracil, leucovorin(MODIFIED FOLFOX6)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously untreated patients with pathologically proven advanced gastric\n             adenocarcinoma with regional LN metastasis are eligible for this study (clinical\n             stage: cT2-4 and N+). At least one measurable regional lymph node metastasis\n             according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.0) [17] is\n             required. Other eligibility criteria include age between 18 and 75 years, Eastern\n             Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, no prior\n             chemotherapy or radiotherapy, and adequate bone marrow, hepatic and renal function\n             (absolute neutrophil count [ANC] \u2265 1.5\u2179109/L, platelet count \u2265 100\u2179109/L, total\n             bilirubin \u2264 1.5\u2179upper limit of normal [ULN], serum transaminases \u2264 2.5\u2179ULN, alkaline\n             phosphatase \u2264 2.5\u2179ULN, serum creatinine \u2264 1.5\u2179ULN or actual or calculated creatinine\n             clearance \u2265 50 mL/min).\n\n        Exclusion Criteria:\n\n          -  Exclusion criteria include clinical stage T1 tumors, clinical or radiologic evidence\n             of distant metastasis, intestinal obstruction or impending obstruction, active tumor\n             bleeding, interstitial pneumonitis or symptomatic pulmonary fibrosis, peripheral\n             neuropathy of National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade \u22651,\n             pregnant or breastfeeding patients, and other serious diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 28, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142322", 
            "org_study_id": "H-0406-127-007"
        }, 
        "intervention": {
            "description": "Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.", 
            "intervention_name": "MODIFIED FOLFOX6", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Seongnam", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Seock-Ah Im, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "response rate by the RECIST criteria", 
            "measure": "response rate", 
            "safety_issue": "No", 
            "time_frame": "22 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142322"
        }, 
        "responsible_party": {
            "name_title": "Seock-Ah Im", 
            "organization": "Seoul National University Hospital"
        }, 
        "secondary_outcome": [
            {
                "description": "toxicity : Grade 3-4 toxicity by the NCI-CTCAE v3.0", 
                "measure": "toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "description": "median value of the time from enrollment to the patient's death", 
                "measure": "median overall survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "median value of the time from enrollment to disease progression, withdrawl of consent, or unacceptable toxicity", 
                "measure": "median time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "the rate of patients whose tumor was completely resected", 
                "measure": "resection rate", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2004", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}